Literature DB >> 21736080

Hepatocellular carcinoma: a review of the surgical approaches to management.

Bernard J DuBray1, William C Chapman, Christopher D Anderson.   

Abstract

Hepatocellular carcinoma (HCC) is increasing in incidence in the United States and is strongly associated with chronic liver disease and cirrhosis. Surgical therapy with liver transplantation or resection remains the mainstay of curative therapy for patients with HCC. Therapeutic decisions in patients with HCC are complex and are best approached via a multidisciplinary group of liver transplant and hepatobiliary surgeons, oncologists, and hepatologists. In this manuscript, we review the current surgical management of HCC.

Entities:  

Mesh：

Year:  2011        PMID： 21736080      PMCID： PMC6188298     

Source DB:  PubMed          Journal:  Mo Med        ISSN： 0026-6620


  22 in total

Review 1.  Surgical treatment of hepatocellular carcinoma: expert consensus statement.

Authors:  William Jarnagin; William C Chapman; Steven Curley; Michael D'Angelica; Charles Rosen; Elijah Dixon; David Nagorney
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

2.  Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation.

Authors:  Carlos Margarit; Alfredo Escartín; Lluis Castells; Víctor Vargas; Elena Allende; Itxarone Bilbao
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

3.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

4.  Risk factors for mortality after surgery in patients with cirrhosis.

Authors:  Swee H Teh; David M Nagorney; Susanna R Stevens; Kenneth P Offord; Terry M Therneau; David J Plevak; Jayant A Talwalkar; W Ray Kim; Patrick S Kamath
Journal:  Gastroenterology       Date:  2007-01-25       Impact factor: 22.682

5.  Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III disease.

Authors:  Jeremy Goodman; Sean C Glasgow; Mark Schnitzler; Jeffrey A Lowell; Surendra Shenoy; Martin D Jendrisak; Niraj Desai; Mauricio Lisker-Melman; Jeffrey Crippin; William C Chapman
Journal:  Arch Surg       Date:  2005-05

6.  Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience.

Authors:  M Del Gaudio; G Ercolani; M Ravaioli; M Cescon; A Lauro; M Vivarelli; M Zanello; A Cucchetti; G Vetrone; F Tuci; G Ramacciato; G L Grazi; A D Pinna
Journal:  Am J Transplant       Date:  2008-04-29       Impact factor: 8.086

Review 7.  Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal.

Authors:  Franco Trevisani; Marta Frigerio; Valentina Santi; Alice Grignaschi; Mauro Bernardi
Journal:  Dig Liver Dis       Date:  2009-10-13       Impact factor: 4.088

8.  Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.

Authors:  William C Chapman; M B Majella Doyle; Jourdan E Stuart; Neeta Vachharajani; Jeffrey S Crippin; Christopher D Anderson; Jeffrey A Lowell; Surendra Shenoy; Michael D Darcy; Daniel B Brown
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

9.  Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers.

Authors:  Hauke Lang; Georgios C Sotiropoulos; Eirini I Brokalaki; Klaus Jürgen Schmitz; Christian Bertona; Gabriele Meyer; Andrea Frilling; Andreas Paul; Massimo Malagó; Christoph E Broelsch
Journal:  J Am Coll Surg       Date:  2007-07       Impact factor: 6.113

10.  Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.

Authors:  Swee H Teh; John Christein; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Stephen Cha; Patrick Kamath; Raymond Kim; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267
View more
  16 in total

Review 1.  Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.

Authors:  Maria Tampaki; George Vasileios Papatheodoridis; Evangelos Cholongitas
Journal:  Clin J Gastroenterol       Date:  2021-03-27

2.  Preoperative ultrasound features as prognostic factors for patients with hepatocellular carcinoma.

Authors:  Zhi-Yong Shen; Gan-Lin Xia; Bing Hu; Yang-Gui Xie; Ming-Feng Wu
Journal:  Radiol Med       Date:  2015-01-09       Impact factor: 3.469

3.  Monoclonal antibody preparation and expression profile analysis of a novel hepatoma associated gene.

Authors:  Yanhong Liu; Jie Song; Yuehui Li; Yanjie Zhao; Qiang Ju; Guohua Zhou; Guancheng Li
Journal:  Pathol Oncol Res       Date:  2013-11-09       Impact factor: 3.201

4.  Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma.

Authors:  Samer Tohme; David A Geller; Jon S Cardinal; Hui-Wei Chen; Vignesh Packiam; Srinevas Reddy; Jennifer Steel; James W Marsh; Allan Tsung
Journal:  HPB (Oxford)       Date:  2012-08-12       Impact factor: 3.647

5.  Systematic review of peri-operative nutritional support for patients undergoing hepatobiliary surgery.

Authors:  Yin Liu; Xiaoyan Xue
Journal:  Hepatobiliary Surg Nutr       Date:  2015-10       Impact factor: 7.293

6.  Should diaphragmatic involvement preclude resection of large hepatic tumors?

Authors:  Nikolaos Arkadopoulos; Maria A Kyriazi; Apostolos Perelas; Kassiani Theodoraki; Evangelia Papantoni; Panagiotis Kokoropoulos; Nikolaos Danias; Vassilios Smyrniotis
Journal:  World J Surg       Date:  2013-09       Impact factor: 3.352

7.  Annexin A2 silencing inhibits invasion, migration, and tumorigenic potential of hepatoma cells.

Authors:  Hai-Jian Zhang; Deng-Fu Yao; Min Yao; Hua Huang; Li Wang; Mei-Juan Yan; Xiao-Di Yan; Xing Gu; Wei Wu; Shao-Lin Lu
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

8.  SJSZ glycoprotein (38 kDa) modulates macrophage type 1/2-related factors at hepatocarcinogenic stage in N-nitrosodiethylamine-treated Balb/c.

Authors:  Jin Lee; Kye-Taek Lim
Journal:  Mol Cell Biochem       Date:  2012-09-07       Impact factor: 3.396

9.  Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.

Authors:  Hai-Jian Zhang; Deng-Fu Yao; Min Yao; Hua Huang; Wei Wu; Mei-Juan Yan; Xiao-Di Yan; Jie Chen
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

10.  Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA.

Authors:  Dandan Yu; Zhizhen Dong; Min Yao; Wei Wu; Meijuan Yan; Xiaodi Yan; Liwei Qiu; Jie Chen; Wenli Sai; Dengfu Yao
Journal:  Tumour Biol       Date:  2012-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.